Annals of Surgical Oncology最新文献

{"title":"Analysis of Influencing Factors and Strategies of Implementing Shared Decision-Making Among Patients with Gastrointestinal Cancer: A Systematic Review and Meta-analysis of Qualitative Studies.","authors":"Mengnan Li, Guang Fu, Wenjuan Mo, Yuanyuan Yan, Xi Chen, Xiong Li","doi":"10.1245/s10434-025-17317-6","DOIUrl":"10.1245/s10434-025-17317-6","url":null,"abstract":"<p><strong>Background: </strong>Over the past 50 years, doctor-patient interactions have moved from paternalistic to patient-centered, emphasizing shared decision-making (SDM). SDM, which involves healthcare professionals and patients making clinical decisions together, is crucial for patient autonomy and is promoted worldwide, yet remains challenging to implement effectively. Our systematic review analyses the influencing factors of implementing shared decision-making in patients with colorectal cancer and summarizes coping strategies.</p><p><strong>Materials and methods: </strong>A systematic search of the PubMed, Embase, Cochrane Library, Web of Science (Core library), Ovid, and EBSCO databases was performed from database inception to 1 September 2024 using a combination of subject words and free words. Qualitative studies on the factors affecting SDM for patients with gastrointestinal cancer were identified, the literature quality was evaluated using the Australian JBI Evidence-based Health Care Center quality evaluation standards for qualitative research, and the results were integrated by a pooled integration method.</p><p><strong>Results: </strong>A total of 37 results were extracted through meta-analysis, summarized into 9 themes, and summarized into 2 subthemes. The results were classified for nonmutually exclusive cases.</p><p><strong>Conclusions: </strong>Medical staff should fully understand patients' needs and preferences for disease and treatment information, strengthen their communication skills regarding SDM, and actively provide effective treatment and care information for patients and their families to promote the implementation of SDM for patients with gastrointestinal tumors.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5183-5199"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Leveraging the National Cancer Database's Representation of Cancer Cases in the United States.","authors":"Anays Murillo, Kelsey S Romatoski, Teviah E Sachs","doi":"10.1245/s10434-025-17383-w","DOIUrl":"10.1245/s10434-025-17383-w","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"4623-4624"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Outcomes for Neoadjuvant Versus Adjuvant Chemotherapy in ER+/HER2- Locally Advanced Breast Cancer.","authors":"Jin Wang, Bin Yang, Lei Bian, Hanqi Zhang, Cheng Peng, Yutian Zou, Hailin Tang","doi":"10.1245/s10434-025-17297-7","DOIUrl":"10.1245/s10434-025-17297-7","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of neoadjuvant chemotherapy (NaCT) over adjuvant chemotherapy (ACT) in enhancing long-term survival for ER+/HER2- breast cancer patients is uncertain. This study compares breast cancer-specific survival (BCSS) between these treatments in patients with stage IIB-IIIC ER+/HER2- breast cancer using the SEER database.</p><p><strong>Methods: </strong>Data from 46,837 patients who underwent chemotherapy and surgery from 2010-2019 were analyzed. Breast cancer-specific survival was assessed by using multivariable Cox regression, inverse probability of treatment weighting (IPTW), and propensity score-matching (PSM) models, along with subgroup analyses.</p><p><strong>Results: </strong>Of the study cohort, 78.4% received ACT, and 21.6% received NaCT. Neoadjuvant chemotherapy usage increased from 15.6% in 2010 to 31.4% in 2019. Multivariable analysis indicated a lower BCSS in the NaCT group (hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.31-1.48, P < 0.001), a trend consistent in IPTW and PSM analyses. However, in specific subgroups, particularly younger patients (<40 years) achieving pathologic complete response (pCR), the NaCT group exhibited better BCSS.</p><p><strong>Conclusions: </strong>Overall, NaCT was associated with poorer survival compared to ACT in ER+/HER2- breast cancer. Nonetheless, certain subgroups, especially younger patients achieving pCR, showed potential benefits from NaCT. Future research should aim to identify markers for optimally applying NaCT in ER+/HER2- breast cancer treatment.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"4890-4898"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Comparative Voice and Swallowing Outcomes After Remote-Access Thyroidectomy: Insights and Future Directions.","authors":"Van Cuong Nguyen, Kyung Tae","doi":"10.1245/s10434-025-17380-z","DOIUrl":"10.1245/s10434-025-17380-z","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5273-5274"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Chemoimmunotherapy for Resectable Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-analysis.","authors":"Lei-Ming Cao, Yi-Fu Yu, Zi-Zhan Li, Guang-Rui Wang, Yao Xiao, Han-Yue Luo, Bing Liu, Lin-Lin Bu","doi":"10.1245/s10434-025-17195-y","DOIUrl":"10.1245/s10434-025-17195-y","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemoimmunotherapy provides a good pathological response in patients with resectable head and neck squamous cell carcinoma (HNSCC). Currently, there is no comprehensive systematic review that rigorously evaluates and summarizes the existing studies. In this study, we aimed to synthesize the results on the efficacy of neoadjuvant chemoimmunotherapy in resectable HNSCC to obtain higher-level evidence.</p><p><strong>Methods: </strong>The PubMed, Web of Science, Scopus, and Academic Search Complete (EBSCO) databases, along with ClinicalTrials.gov, Google Scholar, and conference abstracts, were comprehensively searched. The publication dates of the literature were limited to January 2015-July 2024. Meta-analysis was performed using a random-effects model. The percentage of major pathological response (MPR), pathological complete response (pCR), and overall disease-free survival (DFS) were synthesized. The odds ratios of a combined positive score (CPS) ≥ 20 for MPR and the diagnostic performance of using radiological objective response to determine MPR were further explored.</p><p><strong>Results: </strong>A total of 13 studies with 458 patients who received neoadjuvant chemoimmunotherapy and 443 patients who underwent curative surgery were included. The pooled MPR, pCR, and overall DFS rates were 61%, 37%, and 91%, respectively. The odds ratios of a CPS ≥ 20 for achieving MPR was 2.09 compared with those with a CPS < 20. The sensitivity of using radiological objective response to determine MPR was 0.91 and the specificity was 0.46, with an area under the curve of 0.76.</p><p><strong>Conclusion: </strong>Neoadjuvant chemoimmunotherapy showed promising results for resectable HNSCC. A CPS ≥ 20 can be used to screen for treatment-sensitive patients, and radiological examinations can be used to detect pathological response. Definitive conclusions require data from longer follow-up periods and controlled studies.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5206-5217"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative Transarterial Chemoembolization for Resectable Single Hepatocellular Carcinoma: A Single-Center Cohort Study.","authors":"Sang-Hoon Kim, Ki-Hun Kim, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Woo-Hyoung Kang, Eun-Kyoung Jwa, Byeong-Gon Na, Sung Min Kim, Sung-Gyu Lee","doi":"10.1245/s10434-025-17257-1","DOIUrl":"10.1245/s10434-025-17257-1","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of preoperative transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) remains unclear. This study aimed to investigate the impact of preoperative TACE for resectable solitary HCC.</p><p><strong>Methods: </strong>This retrospective study included 4899 patients who underwent hepatectomy from 2008 to 2019. Survival outcomes were compared before and after propensity score matching (PSM) based on tumor size (≤ 3, 3-5, and > 5 cm) between the preoperative TACE (n = 378) and upfront surgery groups (n = 4521). Cox regression analysis was utilized to identify predictors of overall survival (OS) and recurrence-free survival (RFS).</p><p><strong>Results: </strong>For HCC ≤ 3 cm, OS was similar between the groups but RFS significantly improved in the preoperative TACE group both before (OS: p = 0.44; RFS: p < 0.001) and after (OS: p = 0.84; RFS: p < 0.001) PSM. For HCC 3-5 cm, both OS and RFS significantly improved in the preoperative TACE group, both before (OS: p = 0.038; RFS: p < 0.001) and after (OS: p = 0.038; RFS: p < 0.001) PSM. For HCC > 5 cm, OS was not significantly different but RFS improved in the preoperative TACE group both before (OS: p = 0.42; RFS: p = 0.002) and after (OS: p = 0.42; RFS: p = 0.004) PSM. Additionally, complete lipiodol uptake was associated with better OS (p = 0.032) and RFS (p = 0.045) in tumors 3-5 cm compared with incomplete lipiodol uptake. Multivariate analysis identified preoperative TACE and complete lipiodol uptake as significant factors in improving RFS.</p><p><strong>Conclusion: </strong>Preoperative TACE, achieved as complete lipiodol uptake as possible, is recommended to prevent postoperative recurrence of resectable solitary HCC, particularly for tumors measuring 3-5 cm, due to the clear survival benefits in both OS and RFS.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5008-5020"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Five-Item Modified Frailty Index Predicts Adverse Surgical Outcomes in Patients Undergoing Mastectomy.","authors":"Laetitia S Chiarella, Lioba Huelsboemer, Fortunay Diatta, Felix J Klimitz, Alexander J Kammien, Alejandro Kochen, Sam Boroumand, Omar Allam, Martin Kauke-Navarro, Bohdan Pomahac","doi":"10.1245/s10434-025-17105-2","DOIUrl":"10.1245/s10434-025-17105-2","url":null,"abstract":"<p><strong>Background: </strong>The 5-item modified Frailty Index (mFI-5) is a clinical tool to predict adverse outcomes in surgical patients by assessing five comorbidities: diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, and dependent functional status. It helps to evaluate postoperative complication risks, recovery time, and overall survival, particularly in frail patients undergoing oncological and gynecological surgeries.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed American College of Surgeons, National Surgical Quality Improvement Program data from adult female patients undergoing mastectomy procedures without reconstruction between 2017 and 2022. Patients were selected based on Current-Procedural-Terminology codes, excluding incomplete or non-breast-related cases. Preoperative, perioperative, and 30-day postoperative data were analyzed using logistic and linear regression models, with the mFI-5 cutoff set at 2.</p><p><strong>Results: </strong>Between 2017 and 2022, 860 patients underwent mastectomies at Yale Healthcare Network; 19% (n = 163) had mFI score ≥2. High-risk patients (mFI ≥2) were significantly older (66.32 ± 10.83 years) and had a higher body mass index (33.69 ± 7.73, both p < 0.001). Surgical complications occurred in 11.98% of patients, with a higher rate in the high-risk group (22.7% vs. 9.5%, p < 0.001). Adjusted multivariate logistic regression showed an increased risk of complications in frail patients (aOR 2.66; [1.60-4.43], p < 0.001). Although slight reductions in hospital stay and surgery duration were observed for high-risk patients, these differences were not significant. Sensitivity analysis confirmed higher odds of complications, including acute kidney failure (odds ratio [OR] 9.01) and pneumonia (OR 4.10).</p><p><strong>Conclusions: </strong>The mFI-5 is a robust tool for predicting surgical complications in patients undergoing mastectomy, particularly those with multiple comorbidities.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"4829-4837"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Chemotherapy Response and Genetic Susceptibility in Recently Parous Women with Breast Cancer: A Retrospective Analysis.","authors":"Saya Dennis, Takahiro Tsukioki, Masha Kocherginsky, Andrea Keya Qi, Sarah DeHorn, Michael Gurley, Erica Wrubel, Yuan Luo, Seema Ahsan Khan","doi":"10.1245/s10434-025-17204-0","DOIUrl":"10.1245/s10434-025-17204-0","url":null,"abstract":"<p><strong>Background: </strong>Women with recent parity are at increased short-term breast cancer (BC) risk and face a worse prognosis. The effect of parity on response to neoadjuvant chemotherapy (NAC) is unstudied, and the influence of inherited susceptibility on parity-related short-term risk remains unclear.</p><p><strong>Methods: </strong>A retrospective case-cohort study analyzed women age 50 years or younger with non-metastatic BC diagnosed between 2010 and 2020 who underwent genetic testing and were treated at Northwestern Medicine. Associations between NAC response and recency of parity were evaluated using multivariate logistic regression, stratified by tumor biologic subtypes. Relationships between germline mutations, recency of parity, and BC were explored via multi-state modeling and linear regression.</p><p><strong>Results: </strong>Among 1080 eligible women, 231 received NAC. Treatment response was poorer in parous women with triple-negative tumors than in nullipara women regardless of the recency of parity (P < 0.03). Among 122 women (11.3%) with detectable pathogenic mutations, adjusted analyses with both modeling approaches showed no indications that BRCA1/2 carriers had a greater hazard of a BC diagnosis in the decade after recent parity than nulliparous mutation carriers. For BRCA2 and PALB2 carriers, BC diagnosis occurred less frequently in the postpartum intervals.</p><p><strong>Conclusion: </strong>This study showed a poor response to NAC in parous triple-negative BC (TNBC) patients than in nullipara patients. The effects of immunotherapy-based regimens deserve evaluation in the context of parity. Postpartum BC occurrence is not increased in BRCA1/2 carriers. The effects of rarer susceptibility genes may differ. These important effects of parity on BC in young women and those at genetic risk warrant larger prospective studies.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"4855-4864"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Great Debate: Molecular Testing and Extent of Surgery in Well-Differentiated Thyroid Cancer.","authors":"Cord Sturgeon, Ashok R Shaha, Linwah Yip","doi":"10.1245/s10434-025-17348-z","DOIUrl":"10.1245/s10434-025-17348-z","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"4597-4603"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Voice and Swallowing Changes After Thyroidectomy Using the Gasless Transaxillary, Transoral, and Conventional Transcervical Approaches: A Network Meta-analysis.","authors":"Van Cuong Nguyen, Chang Myeon Song, Yong Bae Ji, Dong Won Lee, Jin Hyeok Jeong, Kyung Tae","doi":"10.1245/s10434-025-17276-y","DOIUrl":"10.1245/s10434-025-17276-y","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluated voice and swallowing outcomes following thyroidectomy by using the gasless transaxillary (GTAA) and transoral (TOA) approaches compared with the conventional transcervical approach (CTA).</p><p><strong>Methods: </strong>A comprehensive search of the PubMed, EMBASE, and Cochrane Library databases was conducted through September 2024. Network meta-analyses were performed on 14 comparative studies, encompassing 1723 patients.</p><p><strong>Results: </strong>Voice handicap index (VHI)-10 scores, highest frequency, and frequency range deteriorated after surgery in all three methods. However, the postoperative voice outcomes of the GTAA and TOA were superior to the conventional approach at all follow-up points up to 3 months after the operation. Specifically, the VHI-10 scores of the GTAA and TOA were significantly lower than those of the CTA at 3 months postoperation. Other acoustic parameters, such as jitter, shimmer, noise-to-harmonic ratio, and intensity range, did not differ among the three methods. The postoperative swallowing impairment score (SIS)-6 of the GTAA and TOA were lower than that of the CTA. Specifically, the SIS-6 of the GTAA was significantly lower than those of the TOA and CTA at 3 months postoperation.</p><p><strong>Conclusions: </strong>The postoperative voice and swallowing outcomes, especially VHI-10, highest frequency, frequency range, and SIS-6, following remote-access thyroidectomy using the GTAA and TOA were superior to those observed with the conventional approach. Given the limited number of studies included, further research is needed to confirm these findings as new studies emerge, especially those with larger sample sizes, diverse populations, different approaches, and extended follow-up periods.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5256-5268"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}